BUFFALO, N.Y., April 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the appointment of key clinical development and regulatory affairs executives to optimally position the company for successful development of its drug candidates. Jean Viallet, M.D., has joined the Company as Chief Development Officer, reporting to the Chief Executive Officer, and will be responsible for overseeing CBLI's clinical strategy, trials and operations, regulatory affairs and preclinical development. The Company also announced the appointment of Gillian Miller, Ph.D., as Senior Director of Regulatory Affairs and Judith Schnyder, MBA as Director of Clinical Operations.
Cleveland BioLabs Strengthens Clinical Development Team
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.